- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00104728
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
Pilot Neoadjuvant Study of ZD1839 (IRESSA®) as Single Agent Preoperative Therapy for Clinical Stage 1A and 1B (T1-2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC) With Molecular Correlates
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be removed.
PURPOSE: This phase II trial is studying how well gefitinib works in treating patients who are undergoing surgery for stage I, stage II, or stage III non-small cell lung cancer.
연구 개요
상세 설명
OBJECTIVES:
Primary
- Determine the effects of neoadjuvant gefitinib on downstream signaling pathways, including Src-Stat3, PI3K/Akt, ERK activity, and Bcl-2 family members in patients with resectable stage I-IIIA non-small cell lung cancer.
- Determine the effects of this drug on cell cycle and apoptosis within the primary tumor, by measuring changes in pre- and post-treatment Ki-67, Mcm2, cleaved caspase-3, and ApoTag, in these patients.
Secondary
- Determine the clinical response rate in patients treated with this drug.
- Determine the pathological response rate, defined as > 95% necrosis or fibrosis in the pathological specimen, in patients treated with this drug.
- Determine the metabolic activity of this drug in these patients.
- Determine the safety, tolerability, and feasibility of this drug, in terms of toxicity and post-treatment resectability, in these patients.
- Correlate plasma and tumor concentrations of this drug with changes in post-treatment molecular markers in these patients.
- Identify a gene profile that predicts response to this drug in these patients.
OUTLINE: This is an open-label, pilot study.
Patients receive oral gefitinib once daily for 4 weeks in the absence of disease progression or unacceptable toxicity.
Within 3 days after completion of gefitinib, patients undergo restaging evaluation. Patients whose disease is still considered resectable proceed to surgery. Patients undergo thoracotomy with lobectomy or pneumonectomy OR sleeve resection. Patients also undergo mediastinal lymph node dissection. After surgical resection, treatment with gefitinib may continue off study at the discretion of the principal investigator.
After completion of study therapy, patients are followed at 30 days, every 4 months for 1 year, every 6 months for 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study within 12.5 months.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Florida
-
Tampa, Florida, 미국, 33612-9497
- H. Lee Moffitt Cancer Center and Research Institute
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Histologically confirmed resectable non-small cell lung cancer (NSCLC), meeting 1 of the following clinical staging criteria:
- Stage IA or IB (T1-2, N0)
- Stage II (T1-2, N1 with negative mediastinoscopy or T3, N0)
Stage IIIA (T3, N1 with negative mediastinoscopy)
- Level 10 hilar nodes may be positive provided mediastinoscopy is negative
The following are not allowed (as evidenced by clinical staging criteria [CT scan, positron-emission tomography (PET) scan, or mediastinoscopy):
- Positive N2 lymph nodes (ipsilateral/subcarinal mediastinal lymph nodes)
- Positive N3 lymph nodes (contralateral mediastinal/hilar and supraclavicular/scalene lymph nodes)
- T4 primary tumor (malignant pleural effusion or mediastinal invasion)
- Symptomatic tumors (T3, N0-1) involving the superior sulcus (i.e., Pancoast tumors)
- Measurable disease by contrast-enhanced CT scan
- No metastatic disease (except peribronchial or hilar lymph node involvement [N1]) by fludeoxyglucose F 18 PET scan
No malignant pleural effusion by preoperative evaluation
- Pleural effusions visible only on CT scan that are not large enough for safe thoracentesis are allowed
No exudative effusions (even if cytologically negative), as evidenced by any of the following:
- Ratio of pleural fluid protein to serum protein > 0.5
- Ratio of pleural fluid lactic dehydrogenase (LDH) to serum LDH ≥ 0.6
- Pleural fluid LDH > 200 IU/L
- No superior vena cava syndrome
- No spinal cord compression
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- Eastern Cooperative Oncology Group (ECOG) 0-1
Life expectancy
- Not specified
Hematopoietic
- WBC ≥ 4,000/mm^3
- Absolute granulocyte count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
Hepatic
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST or ALT ≤ 2 times ULN
- Alkaline phosphatase ≤ 2 times ULN
Renal
- Creatinine < 1.5 times ULN
Cardiovascular
- No uncontrolled ventricular arrhythmia
- No myocardial infarction within the past 3 months
Pulmonary
- Pre-resection FEV_1 > 2.0 L OR
- Predicted post-resection FEV_1 > 1.0 L
No clinically active interstitial lung disease
- Chronic stable asymptomatic radiographic changes allowed
- No post-obstructive pneumonia
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Willing to provide tumor biopsy pre- and post-gefitinib administration AND undergo PET scan
- No known severe hypersensitivity to study drug or any of its excipients
- No uncontrolled major seizure disorder
- No unstable or uncontrolled diabetes mellitus
- No serious infection requiring IV antibiotics
- No grade 3 neuropathy
- No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- No other unstable or serious medical condition that would preclude study treatment or surgery
- No psychiatric disorder that would preclude giving informed consent
- No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow up
- No other significant clinical disorder or laboratory finding that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- No prior or concurrent systemic chemotherapy for NSCLC
Endocrine therapy
- Not specified
Radiotherapy
- No prior or concurrent radiotherapy for NSCLC
Surgery
- Recovered from prior oncologic or other major surgery
- At least 5 years since prior resection of lung disease
- No prior surgery for NSCLC
- No concurrent ophthalmic surgery
Other
- More than 30 days since prior non-approved or investigational drugs
- No other concurrent therapy for NSCLC
- No other concurrent investigational therapy
No concurrent use of any of the following medications:
- Phenytoin
- Carbamazepine
- Barbiturates (e.g., phenobarbital)
- Rifampin
- Hypericum perforatum (St. John's wort)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Neoadjuvant ZD1839 Preoperative Therapy
The ZD1839 250-mg tablet will be taken once a day, every day about the same time. It can be taken with or without food. At the time of surgery, investigators will collect tissue from the participant's tumor once it has been removed. This tissue will be used to study the effect of ZD1839 on tumor growth. |
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Overall Response Rate (ORR)
기간: 3 years
|
Objective Response Rate according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
Investigators planned to use this pilot study of neoadjuvant ZD1839 in patients with resectable NSCLC to specifically correlate molecular parameters to the primary clinical study endpoint clinical response assessed by CT response and PET scan response of the primary tumor.
|
3 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Frequency of Toxicity Related to Study Treatment
기간: 3 years
|
Review of adverse events utilizing Common Toxicity Criteria (CTC) V3.
To estimate the safety, tolerability, and feasibility of preoperative ZD1839 in patients with resectable Stage IA/IB, II and selected IIIA NSCLC by evaluating toxicity and operability after preoperative ZD1839.
|
3 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Eric B. Haura, M.D., H. Lee Moffitt Cancer Center and Research Institute
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- MCC-13922
- IRUSIRES0256 (기타 식별자: AstraZeneca)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
폐암에 대한 임상 시험
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen Breast Cancer...완전한
-
Novartis Pharmaceuticals완전한신경내분비종양 | GI 오리진의 고급 NET | 고급 NET of Lung Origin미국, 콜롬비아, 이탈리아, 대만, 영국, 벨기에, 체코, 독일, 일본, 사우디 아라비아, 캐나다, 네덜란드, 스페인, 대한민국, 레바논, 오스트리아, 중국, 그리스, 남아프리카, 태국, 헝가리, 칠면조, 폴란드, 슬로바키아, 러시아 연방
-
University of UtahNational Cancer Institute (NCI)모병피로 | 좌식 생활 | 전이성 전립선암 | IV기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVA기 전립선암 AJCC(American Joint Committee on Cancer) v8 | IVB기 전립선암 AJCC(American Joint Committee on Cancer) v8미국
-
Jonsson Comprehensive Cancer Center아직 모집하지 않음전립선암 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Rashmi Verma, MDNational Cancer Institute (NCI)모병거세저항성 전립선암 | 전이성 전립선 선암종 | IVB기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center빼는전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterMiraDX모집하지 않고 적극적으로전립선 선암종 | 2기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer Center종료됨거세저항성 전립선암 | 전이성 전립선암 | IVA기 전립선암 AJCC v8 | IVB기 전립선암 AJCC v8 | IV기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.종료됨2기 전립선암 AJCC v8 | IIIA기 전립선암 AJCC v8 | IIIB기 전립선암 AJCC v8 | IIC기 전립선암 AJCC v8 | 3기 전립선암 AJCC v8 | IIIC기 전립선암 AJCC v8 | IIA기 전립선암 AJCC v8 | IIB기 전립선암 AJCC v8 | 1기 전립선암 American Joint Committee on Cancer(AJCC) v8미국
-
Assiut University아직 모집하지 않음South Egypt Cancer Institute(SECI)에서 소아 악성종양 환자에 대한 KDIGO 기준을 사용하여 AKI의 누적 발병률을 확인하기 위해
ZD1839에 대한 임상 시험
-
M.D. Anderson Cancer CenterAstraZeneca완전한
-
SCRI Development Innovations, LLCAstraZeneca완전한
-
Indiana University School of MedicineAstraZeneca종료됨
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)완전한